Ann: Trading Update - H1 FY21, page-275

Hey KS, good to see you still around these parts

So definitely was personally hoping to double double double purely on BTM for reconstruction and wounds alone, without hernia product. There is a large untapped market and with a disruptive product like this there is no reason it shouldn't be able to grow exponentially (maybe contracts with healthcare providers would take a more linear route, but those initial buyers would likely increase their purchases as they became comfortable using the product. Not to mention additional countries, applications, etc).

But covid has obviously thrown a wrench in that. No need to rub it in our faces. No one could've predicted a once in a century pandemic.

Sales staff are still reaching out and converting providers. First sales in new countries, new managerial staff (hopefully due to need, I still trust the board to not overreach, may be my undying optimism).

Once the pandemic gets under control, and it will, we will be made, if we keep this up.

Patience.

IMHO